TALTZ’S Rapid Market Ascent Reflects Its Unparalleled Ability To Transform The Treatment Landscape For Autoimmune Diseases | Delveinsight
TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...
Mid Day17h
Key Highlights
Govt hikes I-T exemption limit to Rs 12 lakh per annum under New Tax Regime Limit for tax deduction on interest income to be doubled to Rs 1 lakh for senior citizens; limit for TDS on rent to be ...
Future Market Insights23h
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Set to Reach USD 47,045.80 Million by 2034 at a 3.6% of CAGR
The global benign prostatic hyperplasia (BPH) prostate treatment market is projected to grow from USD 33.03 billion in 2024 ...